Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics. Hyaluronan is a component of the tumour extracellular matrix. Here, Chauhan et al. show that hyaluronan increases blood pressure in collagen-rich tumours by compressing vessel walls, and that reducing the level of hyaluranon with an angiotensin II inhibitor increases blood flow and drug penetrance in tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, antiangiogenic drugs have a synergistic antitumor effect in combination with radiotherapy and chemotherapy in clinical practice.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [260]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have also shown that widely prescribed ARBs can normalize the stroma and decompress blood vessels, thereby improving the outcome of chemotherapy94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
In the citing paper
“results from our laboratory have shown that the elevated levels of extracellular matrix molecules, including collagen I and hyaluronan, in such tumours can compress blood vessels, impairing their function and resulting in hypoxia94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Hyaluronan has been proposed to be the primary matrix molecule responsible for vessel compression 12 , but its exact mechanism remains unclear.”
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“This might be attributed to resistance induced by the immune microenvironment 39 .”
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628 · cited 2×
“We then studied oxygenation using phosphorescence quenching microscopy 35 .”
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · cited 2×
“…data notwithstanding, it should be noted that antiangiogenic therapy with bevacizumab has failed to prolong survival in desmoplastic tumours such as breast and pancreatic cancer 3 , casting doubt on a possible antiangiogenic mechanism for the benefits observed with angiotensin inhibitors.”
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943 · cited 6×
“Both hyaluronan and collagen fibres contribute to solid stress in tumours: hyaluronan does so by resisting compression, whereas collagen does so by resisting tension and confining the local microenvironment 5 .”
InfluentialSelf-citationSolid stress inhibits the growth of multicellular tumor spheroids
Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J., & Jain, R. K. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-778 · Cited by 859 · cited 1×
“Solid stress (pressure from solid tissue components) accumulates in tumours as cancer and stromal cells proliferate in a confined microenvironment created by crosslinked matrix molecules 4–6 .”
Self-citationEffects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 2×
“The matrix stores and transmits this stress throughout the tumour 7 , collapsing blood vessels to limit perfusion 8,9 .”
Self-citation
Cited by
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Self-citationDelivery technologies for cancer immunotherapy
Riley, R. S., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,607
Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30974-0 · Cited by 2,559
Mao, X., Xu, J., Wang, W., Liang, C., Hua, J., Liu, J., Zhang, B., Meng, Q., Yu, X., & Shi, S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01428-1 · Cited by 2,290
“This vaccine is capable of eliminating CAFs by stimulating a CD8 + T Diverse CAF-targeted depleting immunotherapeutic strategies in preclinical/clinical studies FAP fibroblast activation protein, DC dendritic cell, shA20 A20-specific shRNA, TRP2 tyrosine-related protein 2, AdC68 adenoviral vector of chimpanzee serotyp…”
BackgroundInfluentialElyada, E., Bolisetty, M., Laise, P., Flynn, W. F., Courtois, E. T., Burkhart, R. A., Teinor, J. A., Belleau, P., Biffi, G., Lucito, M. S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0094 · Cited by 2,241
“An inhibitor of this receptor, Losartan, was shown to reduce intratumoral solid stress, leading to increased vascular perfusion and improved drug delivery (48, 78).”
BackgroundEnhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationTurning foes to friends: targeting cancer-associated fibroblasts
Chen, X., & Song, E. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,879
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Self-citationThe tumour microenvironment in pancreatic cancer — clinical challenges and opportunities
Ho, W. J., Jaffee, E. M., & Zheng, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0363-5 · Cited by 1,287
van der Meel, R., Sulheim, E., Shi, Y., Kiessling, F., Mulder, W. J. M., & Lammers, T. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0567-y · Cited by 1,234
Diversity and biology of cancer-associated fibroblasts
Biffi, G., & Tuveson, D. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00048.2019 · Cited by 1,265
Tumor targeting via EPR: Strategies to enhance patient responses
Golombek, S. K., May, J.-N., Theek, B., Appold, L., Drude, N., Kiessling, F., & Lammers, T. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.007 · Cited by 1,262
“Jain and colleagues used losartan to decompress tumor blood vessels, increase vascular perfusion and enhance tumortargeted drug delivery [77].”
MethodNanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
Nakamura, Y., Mochida, A., Choyke, P. L., & Kobayashi, H. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00437 · Cited by 1,101
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Henke, E., Nandigama, R., & Ergün, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00160 · Cited by 1,142
“TGFβ-inhibitor DOX Liu J. et al., 2012 Collagen and HA synthesis Treatment with losartan 5-FU, DOX Diop-Frimpong et al., 2011; Chauhan et al., 2013 Hyaluronic acid Systemic treatment with hyaluronidase Gemcitabine Provenzano et al., 2012; Jacobetz et al., 2013 Hyaluronic acid Systemic treatment…”
BackgroundInfluentialImmunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
The Role of Mechanical Forces in Tumor Growth and Therapy
Jain, R. K., Martin, J. D., & Stylianopoulos, T. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-105259 · Cited by 1,044
“A | Intravital multiphoton microscopy images show treatment with the angiotensin receptor blocker, losartan lowers collagen levels (blue) and increases the density of perfused vessels (green) in an orthotopic mammary adenocarcinoma (EO771) [Reproduced from Reference (135)].”
InfluentialSelf-citationCox, T. R. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00329-7 · Cited by 976
Fibroblast heterogeneity in the cancer wound
Öhlund, D., Elyada, E., & Tuveson, D. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20140692 · Cited by 926
“By reducing collagen and hyaluronic acid production, ARBs can increase vascular perfusion and drug delivery (Chauhan et al., 2013).”
BackgroundExtracellular matrix and its therapeutic potential for cancer treatment
Huang, J., Zhang, L., Wan, D., Zhou, L., Zheng, S., Lin, S., & Qiao, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00544-0 · Cited by 962
Dai, Y., Xu, C., Sun, X., & Chen, X. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 931
Nia, H. T., Munn, L. L., & Jain, R. K. (2020) · Science · doi:10.1126/science.aaz0868 · Cited by 855
“Other targets for reversing fibrosis include the angiotensin system, which modulates CAF activity through the TGF-b and CTGF signaling pathways, contributing to fibrosis (16).”
BackgroundInfluentialSelf-citationYu, J., Zhang, Y., Ye, Y., DiSanto, R., Sun, W., Ranson, D., Ligler, F. S., Buse, J. B., & Gu, Z. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1505405112 · Cited by 848
Strategies for advancing cancer nanomedicine
Chauhan, V. P., & Jain, R. K. (2013) · Nature Materials · doi:10.1038/nmat3792 · Cited by 812
Self-citationImproving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Self-citationPancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
Adamska, A., Domenichini, A., & Falasca, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071338 · Cited by 610
Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060571 · Cited by 623
“For example, losartan can decompress tumor blood vessels, increase vascular perfusion and EPR-targeted drug delivery [145].”
BackgroundConsensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska, P., Alitalo, K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., van Beijnum, J. R., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 590
Self-citationLaklai, H., Miroshnikova, Y. A., Pickup, M. W., Collisson, E. A., Kim, G. E., Barrett, A. S., Hill, R. C., Lakins, J. N., Schlaepfer, D. D., Mouw, J. K., et al. (2016) · Nature Medicine · doi:10.1038/nm.4082 · Cited by 603
Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.005 · Cited by 563
Self-citationStromal biology and therapy in pancreatic cancer: a changing paradigm
Neesse, A., Algül, H., Tuveson, D. A., & Gress, T. M. (2015) · Gut · doi:10.1136/gutjnl-2015-309304 · Cited by 559
“92 Moreover, losartan treatment was accompanied by reduction of pro fi brotic signals such as TGF-β 1, CCN2/CTGF. 92 The authors concluded that angiotensin inhibitors reduce solid stress in tumours, resulting in increased vascular perfusion, oxygen and drug delivery.”
BackgroundThe Extracellular Matrix Modulates the Metastatic Journey
Kai, F., Drain, A. P., & Weaver, V. M. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.03.026 · Cited by 537
“Alternately, Losartan, which is an angiotensin II receptor antagonist used for the treatment of hypertension, has demonstrated anti-contractility activity that was shown to relieve solid stress in tumors and restore vascular integrity (Chauhan et al., 2013).”
BackgroundImproving drug delivery to solid tumors: Priming the tumor microenvironment
Khawar, I. A., Kim, J. H., & Kuh, H.-J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.018 · Cited by 533
Murphy, J. E., Wo, J. Y., Ryan, D. P., Clark, J. W., Jiang, W., Yeap, B. Y., Drapek, L. C., Ly, L., Baglini, C. V., Blaszkowsky, L. S., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0892 · Cited by 522
Self-citationNormalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
“The potential of TGF-β inhibition in reprogramming CAFs toward normalizing ECM and decompressing vessels was realized during the repurposing of antihypertensive drugs that target the renin-angiotensin pathway for cancer treatment (52, 70).”
BackgroundInfluentialSelf-citationCombining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
“We have recently shown that depletion of hyaluronan or collagen can lower solid stress levels in a variety of tumors, including pancreatic cancers (25, 26).”
BackgroundSelf-citationTumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells
Lo, A., Wang, L.-C. S., Scholler, J., Monslow, J., Avery, D., Newick, K., O'Brien, S., Evans, R. A., Bajor, D. J., Clendenin, C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3041 · Cited by 498
“In particular, high levels of HA, known to regulate tumor cell behavior (29, 30) and confer resistance to chemotherapy (18, 20, 21, 30), were detected only in the more desmoplastic tumors.”
Neophytou, C. M., Panagi, M., Stylianopoulos, T., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13092053 · Cited by 456
Self-citationPancreatic Cancer Chemoresistance to Gemcitabine
Amrutkar, M., & Gladhaug, I. (2017) · Cancers · doi:10.3390/cancers9110157 · Cited by 448
“For example, in various genetically-engineered mouse tumor models, pharmacologically-induced stroma remodeling [40,41] or enzyme-mediated degradation of stromal hyaluronan and collagen [42,43], resulted in increased drug delivery and responses to gemcitabine treatment.”
BackgroundSolid stress and elastic energy as measures of tumour mechanopathology
Nia, H. T., Liu, H., Seano, G., Datta, M., Jones, D., Rahbari, N., Incio, J., Chauhan, V. P., Jung, K., Martin, J. D., et al. (2016) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0004 · Cited by 449
Self-citationZhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
“Losartan has been shown to reduce TGF-β-mediated activation of CAFs, reduce the development of desmoplastic tissue components like hyaluronan and collagen produced by CAFs, and increase drug delivery and the effectiveness of immunotherapy [347].”
BackgroundIncio, J., Liu, H., Suboj, P., Chin, S. M., Chen, I. X., Pinter, M., Ng, M. R., Nia, H. T., Grahovac, J., Kao, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1177 · Cited by 456
Self-citationBroadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities
Balachandran, V. P., Beatty, G. L., & Dougan, S. K. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.038 · Cited by 444
El-Sawy, H. S., Al-Abd, A. M., Ahmed, T. A., El-Say, K. M., & Torchilin, V. P. (2018) · ACS Nano · doi:10.1021/acsnano.8b06104 · Cited by 431
Targeting hypoxic tumor microenvironment in pancreatic cancer
Tao, J., Yang, G., Zhou, W., Qiu, J., Chen, G., Luo, W., Zhao, F., You, L., Zheng, L., Zhang, T., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01030-w · Cited by 412
Engineered nanomedicines with enhanced tumor penetration
Ding, J., Chen, J., Gao, L., Jiang, Z., Zhang, Y., Li, M., Xiao, Q., Lee, S. S., & Chen, X. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100800 · Cited by 420
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
Ruscetti, M., Morris, J. P., Mezzadra, R., Russell, J., Leibold, J., Romesser, P. B., Simon, J., Kulick, A., Ho, Y.-J., Fennell, M., et al. (2020) · Cell · doi:10.1016/j.cell.2020.03.008 · Cited by 424
Fluids and their mechanics in tumour transit: shaping metastasis
Follain, G., Herrmann, D., Harlepp, S., Hyenne, V., Osmani, N., Warren, S. C., Timpson, P., & Goetz, J. G. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0221-x · Cited by 412
Feeling Stress: The Mechanics of Cancer Progression and Aggression
Northcott, J. M., Dean, I. S., Mouw, J. K., & Weaver, V. M. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00017 · Cited by 409
“In breast and pancreatic cancers, inhibiting angiotensin with losartan decompressed tumor blood vessels and reduced stromal collagen, which increased vascular perfusion and improved drug delivery (Chauhan et al., 2013).”
BackgroundChen, I. X., Chauhan, V. P., Posada, J., Ng, M. R., Wu, M. W., Adstamongkonkul, P., Huang, P., Lindeman, N., Langer, R., & Jain, R. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815515116 · Cited by 406
“Furthermore, mechanical compression of tumor blood vessels through buildup of physical pressure, termed “solid stress,” by CAFs and matrix leads to tissue hypoxia and low pH (12, 13).”
BackgroundSelf-citationCell Adhesion and Matrix Stiffness: Coordinating Cancer Cell Invasion and Metastasis
Gkretsi, V., & Stylianopoulos, T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00145 · Cited by 390
Self-citationPark, J., Choi, Y., Chang, H., Um, W., Ryu, J. H., & Kwon, I. C. (2019) · Theranostics · doi:10.7150/thno.37198 · Cited by 382
“It has been reported that targeting angiotensin signaling with an angiotensin inhibitor can diminish the ECM, especially collagen and hyaluronan [129, 130].”
BackgroundHemodynamic Forces Tune the Arrest, Adhesion, and Extravasation of Circulating Tumor Cells
Follain, G., Osmani, N., Azevedo, A. S., Allio, G., Mercier, L., Karreman, M. A., Solecki, G., Garcia Leòn, M. J., Lefebvre, O., Fekonja, N., et al. (2018) · Developmental Cell · doi:10.1016/j.devcel.2018.02.015 · Cited by 343
Stromal biology and therapy in pancreatic cancer: ready for clinical translation?
Neesse, A., Bauer, C. A., Öhlund, D., Lauth, M., Buchholz, M., Michl, P., Tuveson, D. A., & Gress, T. M. (2019) · Gut · doi:10.1136/gutjnl-2018-316451 · Cited by 353
Cancer-associated fibroblasts and their influence on tumor immunity and immunotherapy
Barrett, R. L., & Puré, E. (2020) · eLife · doi:10.7554/elife.57243 · Cited by 346
Endothelial Cell Metabolism in Health and Disease
Rohlenova, K., Veys, K., Miranda-Santos, I., De Bock, K., & Carmeliet, P. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.10.010 · Cited by 335
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review
Pinter, M., Jain, R. K., & Duda, D. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3381 · Cited by 339
Self-citationShen, Y., Wang, X., Lu, J., Salfenmoser, M., Wirsik, N. M., Schleussner, N., Imle, A., Freire Valls, A., Radhakrishnan, P., Liang, J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.05.005 · Cited by 339
Han, X., Li, Y., Xu, Y., Zhao, X., Zhang, Y., Yang, X., Wang, Y., Zhao, R., Anderson, G. J., Zhao, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05906-x · Cited by 339
Self-citationTargeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Pinter, M., & Jain, R. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5616 · Cited by 332
“Interim analysis of a recent phase 2 trial—stemming from our preclinical findings (22)—showed encouraging R0 (microscopically margin-negative) resection rates in patients with locally advanced pancreatic ductal adenocarcinoma (PDAC) receiving neoadjuvant losartan plus chemoradiation (23).”
InfluentialSelf-citationMicroenvironmental Determinants of Pancreatic Cancer
Hessmann, E., Buchholz, S. M., Demir, I. E., Singh, S. K., Gress, T. M., Ellenrieder, V., & Neesse, A. (2020) · Physiological Reviews · doi:10.1152/physrev.00042.2019 · Cited by 331
Mechanotransduction in tumor progression: The dark side of the force
Broders-Bondon, F., Nguyen Ho-Bouldoires, T. H., Fernandez-Sanchez, M.-E., & Farge, E. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201701039 · Cited by 319
“Indeed, treatments that degrade stromal collagen or deplete tumor-associated tissues decrease the solid-stress and interstitial pressure, thereby reopening blood vessels, and enhance drug delivery efficiency in vivo in mouse models of pancreatic cancer (Olive et al., 2009; Provenzano et al., 2012; Chauhan et al., 2013…”
BackgroundKoo, S., Park, O. K., Kim, J., Han, S. I., Yoo, T. Y., Lee, N., Kim, Y. G., Kim, H., Lim, C., Bae, J.-S., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c09171 · Cited by 307
Nanomedicine applied to translational oncology: A future perspective on cancer treatment
Bregoli, L., Movia, D., Gavigan-Imedio, J. D., Lysaght, J., Reynolds, J., & Prina-Mello, A. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.08.006 · Cited by 296
“available (29), such as the use of angiotensin (33) or transforming growth factor-β inhibitor to increase the permeability of the tumor vessels (34), or the control of particles size, aspect ratio and surface charge.”
MethodControlling the biodistribution and clearance of nanomedicines
Cabral, H., Li, J., Miyata, K., & Kataoka, K. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00138-1 · Cited by 303
“This strategy has been pursued clinically in patients with colorectal cancer after treatment with bevacizumab 229 and in patients with brain tumours treated with cediranib (AZD2171; a pan-VEGF receptor tyrosine kinase inhibitor) 230 or with cediranib plus temozolomide and X-rays 231–233 .”
Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities
Hu, D., Li, Z., Zheng, B., Lin, X., Pan, Y., Gong, P., Zhuo, W., Hu, Y., Chen, C., Chen, L., et al. (2022) · Cancer Communications · doi:10.1002/cac2.12291 · Cited by 286
“The angiotensin inhibitor losartan inhibited angiotensin-II receptor-1 in CAFs and reduced the expression of downstream TGF-β, connective tissue growth factor (CCN2) and endothelin-1 (ET-1) signaling, reducing stromal collagen and hyaluronan production in tumors and increasing drug and oxygen delivery [331].”
BackgroundCombining microenvironment normalization strategies to improve cancer immunotherapy
Mpekris, F., Voutouri, C., Baish, J. W., Duda, D. G., Munn, L. L., Stylianopoulos, T., & Jain, R. K. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919764117 · Cited by 286
“We have referred to this approach as stroma normalization (27 – 30).”
Self-citationDesign considerations for nanotherapeutics in oncology
Stylianopoulos, T., & Jain, R. K. (2015) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.07.015 · Cited by 280
Self-citationNeurons release serine to support mRNA translation in pancreatic cancer
Banh, R. S., Biancur, D. E., Yamamoto, K., Sohn, A. S. W., Walters, B., Kuljanin, M., Gikandi, A., Wang, H., Mancias, J. D., Schneider, R. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.016 · Cited by 292
“the levels in human PDAC tumors are often greater, leading to the collapse of blood vessels and limiting the nutrient supply (Chauhan et al., 2013).”
BackgroundLi, J., & Kataoka, K. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.0c09029 · Cited by 281
The Extracellular Matrix and Pancreatic Cancer: A Complex Relationship
Weniger, M., Honselmann, K., & Liss, A. (2018) · Cancers · doi:10.3390/cancers10090316 · Cited by 268
“In addition to PEGPH20, HA may also be targeted using angiotensin inhibitors, which have been shown to reduce stromal HA and collagen production [134].”
BackgroundEngineering and physical sciences in oncology: challenges and opportunities
Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273
Self-citationMunn, L. L. (2017) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1370 · Cited by 257
Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy
Glabman, R. A., Choyke, P. L., & Sato, N. (2022) · Cancers · doi:10.3390/cancers14163906 · Cited by 254
Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery
Elliott, R. O., & He, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010122 · Cited by 260
Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies
Mhaidly, R., & Mechta-Grigoriou, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101417 · Cited by 259
“In this sense, the angiotensin inhibitor losartan, reduces stromal collagen and hyaluronan production and decreases the expression of profibrotic signals (TGF b 1, CCN2) [280].”
Zhao, Y., Cao, J., Melamed, A., Worley, M., Gockley, A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 259
“Since reduction in matrix is known to decrease solid stress (9, 25), we next investigated the effects of losartan treatment on solid stress in peritoneal ovarian tumors using the planar-cut technique”
BackgroundMethodResultInfluentialSelf-citationCancer associated fibroblasts in cancer development and therapy
Jia, H., Chen, X., Zhang, L., & Chen, M. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01688-0 · Cited by 224
“…to exhibit anti-tumor effects by targeting the tumor stroma, reducing collagen and hyaluronan production, and consequently decreasing solid stress in tumors, which leads to improved vascular perfusion and drug delivery which, in turn, potentiates chemotherapy in BC and PDAC models [184, 185].”
Ojha, T., Pathak, V., Shi, Y., Hennink, W. E., Moonen, C. T. W., Storm, G., Kiessling, F., & Lammers, T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.07.007 · Cited by 260
Tolaney, S. M., Boucher, Y., Duda, D. G., Martin, J. D., Seano, G., Ancukiewicz, M., Barry, W. T., Goel, S., Lahdenrata, J., Isakoff, S. J., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518808112 · Cited by 258
Self-citationRahbari, N. N., Kedrin, D., Incio, J., Liu, H., Ho, W. W., Nia, H. T., Edrich, C. M., Jung, K., Daubriac, J., Chen, I., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5219 · Cited by 258
Self-citationForce Matters: Biomechanical Regulation of Cell Invasion and Migration in Disease
Kai, F., Laklai, H., & Weaver, V. M. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.03.007 · Cited by 243
Tumor angiogenesis: Current challenges and therapeutic opportunities
Al-Ostoot, F. H., Salah, S., Khamees, H. A., & Khanum, S. A. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100422 · Cited by 229
Ejigah, V., Owoseni, O., Bataille-Backer, P., Ogundipe, O. D., Fisusi, F. A., & Adesina, S. K. (2022) · Polymers · doi:10.3390/polym14132601 · Cited by 234
Interstitial fluid flow in cancer: implications for disease progression and treatment
Munson, J., & Shieh, A. (2014) · Cancer Management and Research · doi:10.2147/cmar.s65444 · Cited by 235
Cruz, E., & Kayser, V. (2019) · Biologics: Targets and Therapy · doi:10.2147/btt.s166310 · Cited by 221
“receptor blockers to increase vessel perfusion, or sonoporation to promote vascular permeability.(169,170)”
BackgroundCancer-associated fibroblasts in pancreatic ductal adenocarcinoma
Zhang, T., Ren, Y., Yang, P., Wang, J., & Zhou, H. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05351-1 · Cited by 214
“Losartan was used to target HA, leading to decreased ECM deposition in an orthotopic tumour, which improved patient survival [117].”
MethodNanomedicine strategies to overcome the pathophysiological barriers of pancreatic cancer
Adiseshaiah, P. P., Crist, R. M., Hook, S. S., & McNeil, S. E. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.119 · Cited by 238
Immune Modulatory Properties of Collagen in Cancer
Rømer, A. M. A., Thorseth, M.-L., & Madsen, D. H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.791453 · Cited by 231
Mhaidly, R., & Mechta‐Grigoriou, F. (2021) · Immunological Reviews · doi:10.1111/imr.12978 · Cited by 231
Endothelial-Mesenchymal Transition in Cardiovascular Disease
Alvandi, Z., & Bischoff, J. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.121.313788 · Cited by 218
Dong, X., Liu, H.-J., Feng, H.-Y., Yang, S.-C., Liu, X.-L., Lai, X., Lu, Q., Lovell, J. F., Chen, H.-Z., & Fang, C. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b04236 · Cited by 223
Self-citationIncio, J., Ligibel, J. A., McManus, D. T., Suboj, P., Jung, K., Kawaguchi, K., Pinter, M., Babykutty, S., Chin, S. M., Vardam, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aag0945 · Cited by 222
Self-citationChemoresistance and the Self-Maintaining Tumor Microenvironment
Yeldag, G., Rice, A., & Del Río Hernández, A. (2018) · Cancers · doi:10.3390/cancers10120471 · Cited by 214
“The disruption of solid stress within the microenvironment by various inhibitors has been shown to improve vascular perfusion and therefore drug delivery [142,143].”
BackgroundImproving cancer therapy through the nanomaterials-assisted alleviation of hypoxia
Sahu, A., Kwon, I., & Tae, G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119578 · Cited by 217
Feng, B., Wu, J., Shen, B., Jiang, F., & Feng, J. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02599-7 · Cited by 210
“Through this mechanism, losartan improves drug and oxygen delivery to TME in breast and pancreatic cancer models [143].”
BackgroundRole of TGFβ in regulation of the tumor microenvironment and drug delivery (Review)
PAPAGEORGIS, P., & STYLIANOPOULOS, T. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.2816 · Cited by 206
Self-citationSeano, G., Nia, H. T., Emblem, K. E., Datta, M., Ren, J., Krishnan, S., Kloepper, J., Pinho, M. C., Ho, W. W., Ghosh, M., et al. (2019) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0334-7 · Cited by 201
Self-citationCancer-associated fibroblasts: Origin, function, imaging, and therapeutic targeting
Rimal, R., Desai, P., Daware, R., Hosseinnejad, A., Prakash, J., Lammers, T., & Singh, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114504 · Cited by 195
Chauhan, V. P., Boucher, Y., Ferrone, C. R., Roberge, S., Martin, J. D., Stylianopoulos, T., Bardeesy, N., DePinho, R. A., Padera, T. P., Munn, L. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.06.003 · Cited by 204
“Since IFP cannot compress blood vessels, we propose that the mechanism of vessel decompression by PEGPH20 is solely a reduction in SS. Importantly, therapies that alleviate SS cause decompression of vessels and improve PDA treatment (Chauhan et al., 2013).”
BackgroundInfluentialSelf-citationReshaping the Tumor Stroma for Treatment of Pancreatic Cancer
Vennin, C., Murphy, K. J., Morton, J. P., Cox, T. R., Pajic, M., & Timpson, P. (2018) · Gastroenterology · doi:10.1053/j.gastro.2017.11.280 · Cited by 202
Metadata
- Authors
- Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., Popović, Z., Huang, P., Bawendi, M. G., Boucher, Y., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-10-01
- Volume
- 4
- Issue
- 1
- Pages
- 2516-2516
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3806395
- OpenAlex
- W1603491949
- Cited by
- 1,031
- References
- 64
- Citations by year
- 2026: 85 · 2025: 77 · 2024: 86 · 2023: 101 · 2022: 96 · 2021: 128 · 2020: 92 · 2019: 82 · 2018: 66 · 2017: 69 · 2016: 56 · 2015: 54 · 2014: 31 · 2013: 7
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- Lustgarten Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (1s10rr027070-01, W81XWH, CA080124, CA085140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, T32CA073479, R01CA085140, P01-CA126642, R01-CA11576, P01CA080124, R01CA126642, R01CA098706)
- National Institute of Biomedical Imaging and Bioengineering (P41EB015903)
- National Center for Research Resources (S10-RR027070)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- losartan, hyaluronic acid, tumor stroma, solid stress, collagen, TGF-β1, connective tissue growth factor, endothelin-1, drug delivery, tumor hypoxia, chemotherapy potentiation, breast cancer, pancreatic cancer, drug repurposing
- MeSH terms
- Angiotensins, Animals, Antineoplastic Agents, Collagen, Drug Synergism, Female, Fluorouracil, Humans, Hyaluronic Acid, Mammary Neoplasms, Experimental, Pancreatic Neoplasms, Stress, Mechanical, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Stromal Cells, Endothelin-1, Losartan, Mechanotransduction, Cellular, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers, Mice, Transforming Growth Factor beta1, Connective Tissue Growth Factor, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.